News

Roderick Spears, MD, FAHS, FAAN, professor of neurology, University of Pennsylvania, discussed the need to raise awareness of migraine and how the community can build upon the progress made.

The workshop included weekly virtual meetings on journaling, meditation, yoga therapeutics, among other activities.

Neurology News Network for the week ending October 15, 2021. [WATCH TIME: 3 minutes]

Action is not anticipated to be taken this month, with a new target action date to be provided.

Investigators concluded that treatment with high-efficacy disease-modifying therapies was a protective factor in disease prognosis.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 15, 2021.

The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University spoke on the safety and efficacy of ublituximab in treating patients with relapsing forms of multiple sclerosis. [WATCH TIME: 4 minutes]

Data presented at the ECTRIMS Congress 2021 noted immunity was reduced in patients taking anti-CD20 monoclonal antibodies.

The director of the Multiple Sclerosis Center at Ochsner Health discussed the open-label extension data presented at ECTRIMS Congress on ATA188 in progressive MS. [WATCH TIME: 4 minutes]

The treatment effect observed from nabiximols (Sativex; GW Pharmaceuticals) was significant at all 1-week time points over the course of the 12-week study.

Lawrence Steinman, MD, Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University, discussed findings presented at ECTRIMS 2021.

Data from the EXPAND trial show that after 12 months of treatment, changes on retinal nerve fiber layer thickness favored those on siponimod rather than the placebo group.

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic provided context on whether efficacy outcomes should be weighed more than mechanistic action when evaluating MSC-NTF cell therapies. [WATCH TIME: 3 minutes]

The headache specialist at Jefferson Headache Center discussed the array of issues patients with migraine face and why her personal experience may resonate with patients. [WATCH TIME: 3 minutes]

In addition to the data presented at ECTRIMS Congress 2021, Atara Bio is investigating the therapy in an ongoing and enrolling phase 2 study, EMBOLD (NCT03283826), which is expected to read out interim results in early 2022.

After vaccination, patients showed no increased risk of relapse activity, but had varied immune response depending on the disease-modifying therapy they were treated with.

Investigators found that Hispanic and African American patients had an increased risk of developing ambulatory disability, when compared to Caucasian patients with MS.

The clinical research director of the USCF Multiple Sclerosis Center discussed the importance of improving knowledge and education for patients with NMOSD, as well as strategies to do so. [WATCH TIME: 3 minutes]

In data presented at ECTRIMS 2021, from years 1-5, the proportions of patients with relapsing multiple sclerosis achieving NEDA-3 status ranged from 63%to 75%.

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the use of MSC-NTF cells in progressive MS and the data backing this approach. [WATCH TIME: 3 minutes]

The registered dietitian at Ann & Robert H. Lurie Children’s Hospital of Chicago provided knowledge on the how and why diets are constructed for patients with epilepsy.

Investigators highlighted the need to integrate research frameworks to analyze and understand these interrelationships, developing appropriate interventions for the Black, Latinx, and Hispanic populations with NMOSD and MS.

The research chair for Parkinson’s Disease and Movement Disorders at University of Cincinnati Health discussed the therapy’s results in a study of its effect on Parkinson disease. [WATCH TIME: 6 minutes]

Discussing the 3 FDA-approved treatments for NMOSD, the clinical research director of the UCSF Multiple Sclerosis Center commented on the positive impact, as well as resultant barriers to care. [WATCH TIME: 4 minutes]

In the cohort of 14 patients with preoperative impulsive and compulsive behavior burden, 6 patients demonstrated clinically relevant improvement on QUIP-RS, while 1 worsened and 7 remained stable.

The neurologist at Wayne State University provided background on why there needs to be a continued focus on including and studying African American patients with NMOSD in trials. [WATCH TIME 3 minutes]

Investigators observed a significant difference in the hazard ratio change on NPI apathy score within the first 100 days, suggesting an early treatment effect.

A large-scale rural population study included approximately 27,935 men and women, finding that sleep quality might predict risk of coronary heart disease.